Comparison · NCT01619176-e18d81e5
Acupuncture vs Control: ACR20 Response Rate at 3 Months
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Acupuncture vs Control: ACR20 Response Rate at 3 Months. Trial comparisons, record NCT01619176-e18d81e5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01619176-e18d81e5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.833 | 0.436 | 0.97 | wilson | |
| Risk in group 2 | 0.75 | 0.301 | 0.954 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0833 | -0.363 | 0.553 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.569 | 2.17 | log | |
| Odds ratio, group 1 over group 2 | 1.67 | 0.0736 | 37.7 | log | |
| Number needed to treat, for one more participant with the outcome on Acupuncture than on Control | 12 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Acupuncture | Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)~methotrexate: methotrexate: 7.5mg/week to 15mg/week for 3 months~non-steroidal anti-inflammatory drug (NSAID): NSAID: 100mg twice a day for 3 months~leflunomide: leflunomide: 20mg/day for 3 months~Acupuncture: 30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20. | 5 | 6 | OG000 |
| Group 2 | Control | Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)~methotrexate: methotrexate: 7.5mg/week to 15mg/week for 3 months~non-steroidal anti-inflammatory drug (NSAID): NSAID: 100mg twice a day for 3 months~leflunomide: leflunomide: 20mg/day for 3 months | 3 | 4 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- ACR20 Response Rate at 3 Months
- Description
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters:~acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire~The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
- Time frame
- From baseline to three months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood
- NCT number
- NCT01619176
- Phases
- NA
- Conditions
- Rheumatoid Arthritis
- Interventions
- methotrexate, non-steroidal anti-inflammatory drug (NSAID), leflunomide, methotrexate, non-steroidal anti-inflammatory drug (NSAID), leflunomide, Acupuncture
- Lead sponsor
- Chinese Academy of Sciences
- Results first posted
- 2023-09-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01619176?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01619176-e18d81e5